Home/Pipeline/AI Programme - Influenza

AI Programme - Influenza

Influenza

DiscoveryActive - Target/Candidate ID

Key Facts

Indication

Influenza

Phase

Discovery

Status

Active - Target/Candidate ID

Company

Poolbeg Pharma

About Poolbeg Pharma

Poolbeg Pharma is a UK-based, AIM-listed biotech founded in 2021 with a mission to develop high-value therapies for large markets with unmet needs. Its strategy centers on a capital-efficient model of de-risking assets through early clinical development before pursuing partnerships. Key achievements include securing FDA Orphan Drug Designation for its lead oncology asset, POLB 001, and building a proprietary AI discovery platform powered by unique human challenge trial data. The company aims to accelerate pipeline growth while minimizing substantial capital expenditure.

View full company profile

Therapeutic Areas

Oncology Supportive Care Metabolic Disease (Obesity)Infectious Disease

Other Influenza Drugs

Drug	Company	Phase	Status
PanCytoVir™ (oral probenecid)	TrippBio	IND Submitted	Active
Next-Gen / Universal Flu Vaccines	CSL Seqirus	Research / Early Clinical	Active
Influenza Antibodies	new/era/mabs	Research/Pre-clinical	Active
Influenza Countermeasure Program	DynPort Vaccines	Not Specified	Active
Influenza Vaccine	Medigen	Preclinical	Active
Nasal Influenza Vaccine	Abera Bioscience	Pre-clinical	Active
Zapnometinib (ATR-002)	Atriva Therapeutics	Phase 2	Active
EV25	Eradivir	Pre-clinical	Active
Not Specified	New Amsterdam Sciences	Pre-clinical	Active
Influenza Program	Arisan Therapeutics	Preclinical	Active
Universal Influenza Vaccine	Orlance	Pre-IND	Active
Enhanced Seasonal Influenza Vaccine	Orlance	Research	Active